Malaria

The Vaccine Book

Volumn , Issue , 2003, Pages 291-310

  Hoffman, Stephen L ^a,c   Richie, Thomas L ^b  

^a CELERA GENOMICS   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c SANARIA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903342770     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012107258-2/50023-8     Document Type: Chapter

References (89)

1. Aidoo M., Lalvani A., Allsopp C.E., Plebanski M., Meisner S.J., Krausa P., et al. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 1995, 345:1003-1007.
2. Alonso P.L., Smith T., Armstrong Schellenberg J.R., Masanja H., Mwankusye S., Urassa H., et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994, 344:1175-1181.
3. Baird J.K. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol. Today 1995, 11:105-111.
4. Baird J.K., Masbar S., Basri H., Tirtokusumo S., Subianto B., Hoffman S.L. Age-dependent susceptibility to severe disease with primary exposure to Plasmodium falciparum. J. Infect. Dis. 1998, 178:592-595.
5. Berzins K., Perlmann P. Malaria vaccines: Attacking infected erythrocytes. Malaria Vaccine Development: A Multi-Immune Response Approach 1996, 105-144. ASM Press, Washington, DC. S.L. Hoffman (Ed.).
6. Bojang K.A., Obaro S.K., D'Alessandro U. Randomized, double-blind controlled trial of efficacy of RTS, S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: A randomised trial. Lancet 2001, 358:1927-1934.
7. Bouharoun Tayoun H., Oeuvray C., Lunel F., Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 1995, 182:409-418.
8. Bowman S., Lawson D., Basham D., Brown D., Chillingworth T., Churcher C.M., et al. The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum. Nature 1999, 400(6744):532-538.
9. Breman J.G. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 2001, 64(1-2 Suppl):1-11.
10. Brown G.V., Rogerson S.J. Preventing cytoadherence of infected erythrocytes to endothelial cells and noninfected erythrocytes. Malaria Vaccine Development: A Multi-Immune Response Approach 1996, 145-166. ASM Press, Washington, DC. S.L. Hoffman (Ed.).
11. Clark I.A., Schofield L. Pathogenesis of malaria. Parasitol. Today 2000, 16(10):451-454.
12. Clyde D.F., McCarthy V.C., Miller R.M., Hornick R.B. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 1973, 266:398-401.
13. Clyde D.F., Most H., McCarthy V.C., Vanderberg J.P. Immunization of man against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 1973, 266:169-177.
14. Clyde D.F., McCarthy V.C., Miller R.M., Woodward W.E. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 1975, 24:397-401.
15. Cohen S., McGregor I.A., Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961, 192:733-737.
16. + T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 1999, 18(7-8):623-632.
17. Doolan D.L., Hoffman S.L., Southwood S., Wentworth P.A., Sidney J., Chestnut R.W., et al. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by HLA-A and HLA-B supertypes alleles. Immunity 1997, 7:97-112.
18. + T cells in the Plasmodium yoelii model. J. Immunol. 1999, 163:884-892.
19. Doolan D.L., Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J. Immunol. 2000, 165:1453-1462.
20. Duffy P.E., Craig A.G., Baruch D.I. Variant proteins on the surface of malaria-infected erythrocytes-Developing vaccines. Trends Parasitol. 2001, 17(8):354-356.
21. Edelman R., Hoffman S.L., Davis J.R., Beier M., Sztein M.B., Losonsky G., et al. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J. Infect. Dis. 1993, 168:1066-1070.
22. Egan J.E., Hoffman S.L., Haynes J.D., Sadoff J.C., Schneider I., Grau G.E., et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 1993, 49:166-173.
23. Felger I., Irion A., Steiger S., Beck H.P. The epidemiology of multiple Plasmodium falciparum infections. 2. Genotypes of merozoite surface protein 2 of Plasmodium falciparum in Tanzania. Trans. R. Soc. Trop. Med. Hyg. 1999, 93(Suppl 1):3-9.
24. Flanagan K.L., Lee E.A., Gravenor M.B., Reece W.H., Urban B.C., Doherty T., et al. Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays. J. Immunol. 2001, 167(8):4729-4737.
25. Fries L.F., Gordon D.M., Richards R.L., Egan J.E., Hollingdale M.R., Gross M., et al. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:358-362.
26. Gallup J.L., Sachs J.D. The economic burden of malaria. Am. J. Trop. Med. Hyg. 2001, 64(1-2 Suppl):85-96.
27. Gandon S., Mackinson M.J., Nee S., Read A.F. Imperfect vaccines and the evolution of pathogen virulence. Nature 2001, 414(6865):751-756.
28. Gardner M.J., Tettelin H., Carucci D.J., Cummings L.M., Aravind L., Koonin E.V., et al. Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science 1998, 282:1126-1132. [Published erratum appears].
29. Gardner M.J., Tettelin H., Carucci D.J., Cummings L.M., Aravind L., Koonin E.V., et al. Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science 1998, 282:1827.
30. Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., Paulsen, I. T., James, K., Eisen, J.A., Rutherford, K., Salzberg, S. L., Craig, A., Kyes, S., Chan, M.-S., Nene, V., Shallom, S. J., Suh, B., Peterson, J., Angiuoli, S., Pertea, M., Allen, J., Selengut, J., Haft, D., Mather, M. W., Vaidya, A. B., Martin, D., Fairlamb, A. H., Fraunholz, M. J., Roos, D. S., Ralph, S., McFadden, G. I., Cummings, L. M., Subramanian, G. M., Mungall, C., Venter, J. C., Carucci, D. J., Hoffman, S. L., Newbold, C., Davis, R. W., Fraser, C. M., Barrell, B. The genome sequence of the human malaria parasite Plasmodium falciparum. Science. In press, will be published on October 2, 2002.
31. Genton B.,Yaman F., Anders R., Saul A., Brown G., Pye D., et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000, 18(23):2504-2511.
32. Genton B., Betuela I., Felger I., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase I/IIb trial in Papua New Guinea. J. Infect. Dis. 2002, 185(6):820-827.
33. Graves P., Gelbrand H. Vaccines for preventing malaria. Cochrane Review Issue 3. Update Software, Oxford. Electronic Citation 2001.
34. Herrington D., Davis J., Nardin E., Beier M., Cortese J., Eddy H., et al. Successful immunization of humans with irradiated sporozoites: Humoral and cellular responses of the protected individuals. Am. J. Trop. Med. Hyg. 1991, 45:539-547.
35. Hoffman S.L., Edelman R., Bryan J., Schneider I., Davis J., Sedegah M., et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria and squalence as adjuvant. Am. J. Trop. Med. Hyg. 1994, 51:603-612.
36. Hoffman S.L., Franke E.D., Hollingdale M.R., Druilhe P. Attacking the infected hepatocyte. Malaria Vaccine Development: A Multi-Immune Response Approach 1996, 35-75. ASM Press, Washington, DC. S.L. Hoffman (Ed.).
37. Hoffman S.L., Rogers W.O., Carucci D.J., Venter J.C. From genomics to vaccines: Malaria as a model system. Nat. Med. 1998, 4:1351-1353.
38. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 2002, 185(8):1155-1164.
39. Hoffman S.L., Subramanian G.M., Collins F.H., Venter J.C. Plasmodium, human, and Anopheles genomics and malaria. Nature 2002, 415(6872):702-709.
40. Holder A.A. Preventing merozoite invasion of erythrocytes. Malaria Vaccine Development: A Multi-Immune Response Approach 1996, 77-104. ASM Press, Washington, DC. S.L. Hoffman (Ed.).
41. Jones T.R., Obaldia N., Gramzinski R.A., Charoenvit Y., Kolodny N., Kitov S., et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 1999, 17:3065-3071.
42. Kaslow D.C. Transmission-blocking vaccines. Malaria Vaccine Development: A Multi-Immune Response Approach 1996, 181-227. ASM Press, Washington, DC. S.L. Hoffman (Ed.).
43. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 2001, 183(4):640-647.
44. + cytotoxic T cell clone recognizing sporozoite surface protein 2. Infect. Immun. 1994, 62:2979-2983.
45. Lalvani A., Hurt N., Aidoo M., Kibatala P., Tanner M., Hill A.V. Cytotoxic T lymphocytes to Plasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. Eur. J. Immunol. 1996, 26(4):773-779.
46. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409(6822):860-921.
47. Le T.P., Coonan K.M., Hedstrom R.C., Charoenvit Y., Sedegah M., Epstein J.E., et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000, 18:1893-1901.
48. Long C.A., Hoffman S.L. Malaria from infants to genomics to vaccines. Science 2002, 297:345-347.
49. Lopez J.A., Weilenman C., Audran R., Roggero M.A., Bonelo A., Tiercy J.M., et al. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 2001, 31(7):1989-1998.
50. Malik A., Egan J.E., Houghten R.A., Sadoff J.C., Hoffman S.L. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:3300-3304.
51. McGregor I.A., Carrington S.P. Treatment of East African P. falciparum malaria with West African human γ-globulin. Trans. R. Soc. Trop. Med. Hyg. 1963, 57(3):170-175.
52. Mendis K., Sina B.J., Marchesini P., Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 2001, 64(1-2 Suppl.):97-106.
53. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Castro Z.R., Nussenzweig R.S., Schmeckpeper B., et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 2000, 182(5):1486-1496.
54. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., Nussenzweig R.S., Schneider M., Tiercy J.M., et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 2001, 166(1):481-489.
55. Narum D.L., Kumar S., Rogers W.O., Fuhrmann S.R., Liang H., Oakley M., et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect. Immun. 2001, 69(12):7250-7253.
56. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
57. O'Hagan D., Singh M., Ugozzoli M., Wild C., Barnett S., Chen M., et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J. Virol. 2001, 75(19):9037-9043.
58. Ockenhouse C.F., Sun P.F., Lanar D.E., Wellde B.T., Hall B.T., Kester K., et al. Phase I/IIa safety, immunogenicity, and efficacy of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 1998, 177:1664-1673.
59. Playfair J.H.L. An antitoxic vaccine for malaria?. Malaria Vaccine Development: A Multi-Immune Response Approach 1996, 167-180. ASM Press, Washington, DC. S.L. Hoffman (Ed.).
60. + T cell clones against Plasmodium yoelii liver stages. J. Immunol. 1993, 150:1471-1478.
61. Richie T.L., Saul A. Progress and challenges for malaria vaccines. Nature 2002, 415(6872):694-701.
62. Rieckmann K.H., Carson P.E., Beaudoin R.L., Cassells J.S., Sell K.W. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 1974, 68:258-259.
63. Rieckmann K.H., Beaudoin R.L., Cassells J.S., Sell D.W. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull. World. Health. Organ. 1979, 57(Suppl. 1):261-265.
64. Rogers W.O., Weiss W.R., Kumar A., Aguiar J.C., Tine J.A., Gwadz R., Harre J.G., Gowda K., Rathore D., Kumar S., Hoffman S.L. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus, boosting immunization regimen. Infect. Immun. 2002, 70(8):4329-4335.
65. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989, 341:323-325.
66. Sabchareon A., Burnouf T., Ouattara D., Attanath P., Bouharoun-Tayoun H., Chatavanich P., et al. Parasitologic and clinical human response to immunoglobullin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 1991, 45(3):297-308.
67. Sakai T., Horii T., Hisaeda H., Zhang M., Ishii K., Nakano Y., et al. DNA immunization with Plasmodium falciparum serine repeat antigen: Regulation of humoral immune response by coinoculation of cytokine expression plasmid. Parasitol. Int. 1999, 48(1):27-33.
68. + T cell induction and complete, protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 1998, 4:397-402.
69. Schofield L., Hewitt M.C., Evans K., Siomos M.A., Seeberger P.H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002, 418(6899):785-789.
70. + T cells and antibodies required for immunity of malaria sporozoites. Nature 1987, 330:664-666.
71. + cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. J. Immunol. 1992, 149:966-971.
72. Sedegah M., Jones T.R., Kaur M., Herdstrom R.C., Hobart P., Tine J.A., et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7648-7653.
73. Sedegah M., Weiss W., Sacci J.B., Charoenvit Y., Hedstrom R., Gowda K., et al. Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF encoding plasmid DNA and boosting with antigen expressing recombinant poxivirus. J. Immunol. 2000, 164:5905-5912.
74. Sim B.K., Narum D.L., Liang H., Fuhrmann S.R., Obaldia N., Gramzinski R., et al. Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Mol. Med. 2001, 7(4):247-254.
75. Sinnis P., Nussenzweig V. Preventing sporozoite invasion of hepatocytes. Malaria Vaccine Development: A Multi-Immune Response Approach 1996, 15-33. ASM Press, Washington, DC. S.L. Hoffman (Ed.).
76. Snow R.W., Omumbo J.A., Lowe B., Molyneux C.S., Obiero J.O., Palmer A., et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 1997, 349:1650-1654.
77. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. New England J. Medicine 1997, 336:86-91.
78. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 1998, 178:1139-1144.
79. Valero M.V., Amador L.R., Galindo C., Figueroa J., Bello M.S., Murillo L.A., et al. Vaccination with SPf66, a chemical synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 1993, 341:705-710.
80. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., et al. The sequence of the human genome. Science 2001, 291(5507):1304-1351.
81. + T cell- and IFN-gamma-dependent elimination of infected hepatocytes. J. Immunol. 1996, 157:4061-4067.
82. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476-480.
83. + Type 1 responses in humans by a malaria DNA vaccine. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(19):10817-10822.
84. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:573-576.
85. Weiss W.R., Berzovsky J.A., Houghten R.A., Sedegah M., Hollingdale M., Hoffman S.L. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J. Immunol. 1992, 149:2103-2109.
86. Weiss W.R., Ishii K.J., Hedstrom R.C., Sedegah M., Ichino M., Barnhart K., et al. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J. Immunol. 1998, 161:2325-2332.
87. Wizel B., Houghten R., Church P., Tine J.A., Lanar D.E., Gordon D.M., et al. HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. J. Immunol. 1995, 155:766-775.
88. Wizel B., Houghten R.A., Parker K., Coligan J.E., Church P., Gordon D.M., et al. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum surface sporozoite protein 2. J. Exp. Med. 1995, 182:1435-1445.
89. Wu S., Beier M., Sztein M.B., Galen J., Pickett T., Holder A.A., et al. Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium falciparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C. J. Biotechnol. 2000, 83(1-2):125-135.